UPDATE: Goldman Sachs Downgrades Syneos (SYNH) to Neutral

(Updated - March 30, 2020 5:48 AM EDT)

(updating comment)

Goldman Sachs analyst Robert Jones downgraded Syneos (NASDAQ: SYNH) from Buy to Neutral with a price target of $45.00 (from $79.00).

The analyst comments "We see risks to this segment as many health systems had banned in-person interactions with sales reps as early as 3/13. It is unclear how much of this work can be conducted remotely. We also are concerned that communications/media may be a cost-cutting area for biopharma
companies."

For an analyst ratings summary and ratings history on Syneos click here. For more ratings news on Syneos click here.

Shares of Syneos closed at $41.60 yesterday.

You May Also Be Interested In

• JPMorgan Downgrades Monster Beverage (MNST) to Neutral
• Reckitt Benckiser (RKT:LN) (RBGLY) PT Raised to GBP61 at Barclays
• Storebrand (STB:NO) (SREDY) PT Raised to NOK120 at Berenberg